文献速递肾小球疾病

IgA肾病蛋白编码变异的全基因组关联分析

Genome-Wide Association Analysis of Protein-Coding Variants in IgA Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2023-10-02

研究对8529例IgA肾病患者和23224例对照进行三阶段外显子芯片关联分析,发现VEGFA罕见错义变异使IgA肾病风险约增加两倍,PKD1L3常见变异与较低触珠蛋白水平相关。VEGFA变异还与肾脏病进展风险升高相关。

要点

  • VEGFA罕见错义变异与IgA肾病风险升高相关(OR 1.97)。
  • PKD1L3常见错义变异与较低触珠蛋白蛋白水平相关(OR 1.16)。
  • VEGFA变异与IgA肾病肾脏病进展风险升高相关(HR 2.99)。

核心结论

  • 研究在VEGFA和PKD1L3中识别出两个新的IgA肾病风险变异,有助于扩展对IgA肾病易感遗传基础的理解。

研究设计与样本

  • 三阶段基于外显子芯片的编码变异关联研究,纳入8529例IgA肾病患者和23224例对照,均为汉族 ancestry。
  • 对芯片未覆盖的罕见编码变异进行测序分析,并使用分子动力学模拟表征VEGFA突变对蛋白结构和功能的影响。

主要发现

  • 发现VEGFA中一个新的罕见非同义风险变异(OR 1.97;95%CI 1.61至2.41;P=3.61×10^-11)。
  • VEGFA进一步测序显示,2148例病例中其他罕见变异的携带者数量是2732例对照的两倍。
  • 发现PKD1L3中一个常见非同义风险变异(OR 1.16;95%CI 1.11至1.21;P=1.43×10^-11),与较低触珠蛋白蛋白水平相关。
  • 罕见VEGFA突变可导致构象改变并增加VEGFA与其受体的结合亲和力。
  • 该VEGFA变异与IgA肾病肾脏病进展风险升高相关(HR 2.99;95%CI 1.09至8.21;P=0.03)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Genome-wide association studies have identified nearly 20 IgA nephropathy susceptibility loci. However, most nonsynonymous coding variants, particularly ones that occur rarely or at a low frequency, have not been well investigated. The authors performed a chip-based association study of IgA nephropathy in 8529 patients with the disorder and 23,224 controls. They identified a rare variant in the gene encoding vascular endothelial growth factor A (VEGFA) that was significantly associated with a two-fold increased risk of IgA nephropathy, which was further confirmed by sequencing analysis. They also identified a novel common variant in PKD1L3 that was significantly associated with lower haptoglobin protein levels. This study, which was well-powered to detect low-frequency variants with moderate to large effect sizes, helps expand our understanding of the genetic basis of IgA nephropathy susceptibility. BACKGROUND: Genome-wide association studies have identified nearly 20 susceptibility loci for IgA nephropathy. However, most nonsynonymous coding variants, particularly those occurring rarely or at a low frequency, have not been well investigated. METHODS: We performed a three-stage exome chip-based association study of coding variants in 8529 patients with IgA nephropathy and 23,224 controls, all of Han Chinese ancestry. Sequencing analysis was conducted to investigate rare coding variants that were not covered by the exome chip. We used molecular dynamic simulation to characterize the effects of mutations of VEGFA on the protein's structure and function. We also explored the relationship between the identified variants and the risk of disease progression. RESULTS: We discovered a novel rare nonsynonymous risk variant in VEGFA (odds ratio, 1.97; 95% confidence interval [95% CI], 1.61 to 2.41; P = 3.61×10 -11 ). Further sequencing of VEGFA revealed twice as many carriers of other rare variants in 2148 cases compared with 2732 controls. We also identified a common nonsynonymous risk variant in PKD1L3 (odds ratio, 1.16; 95% CI, 1.11 to 1.21; P = 1.43×10 -11 ), which was associated with lower haptoglobin protein levels. The rare VEGFA mutation could cause a conformational change and increase the binding affinity of VEGFA to its receptors. Furthermore, this variant was associated with the increased risk of kidney disease progression in IgA nephropathy (hazard ratio, 2.99; 95% CI, 1.09 to 8.21; P = 0.03). CONCLUSIONS: Our study identified two novel risk variants for IgA nephropathy in VEGFA and PKD1L3 and helps expand our understanding of the genetic basis of IgA nephropathy susceptibility.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Li M, Wang YN, Wang L, et al. Genome-Wide Association Analysis of Protein-Coding Variants in IgA Nephropathy. J Am Soc Nephrol. 2023. PMID: 37787447. doi:10.1681/ASN.0000000000000222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。